In this article, we will discuss Olaparib (Description-4). So, let’s get started. Absorption Following oral administration of olaparib, absorption is rapid with median peak plasma concentrations typically achieved 1.5 hours after dosing. An AUC mean accumulation ratio of 1.8 is observed at steady state following multiple dosing of 300 mg tablets twice daily.
Category: Olaparib
In this article, we will discuss Olaparib (Description-3). So, let’s get started. Pharmacokinetics Olaparib is available as a tablet and capsule formulation. The oral bioavailability of the tablet formulation is higher than the capsule formulation. Population pharmacokinetic analyses have shown that the steady state exposure (AUC) following 300 mg tablet twice daily was 77% higher […]
In this article we will discuss Olaparib (Description-2)
In this article, we will discuss Olaparib (Description-1). So, let’s get started. Olaparib is an inhibitor of the mammalian polyadenosine 5’-diphosphoribose polymerase (PARP) enzyme. The chemical name is 4-[(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4- fluorophenyl)methyl]phthalazin-1(2H)-one.
In this article, we will discuss Olaparib (Overdosage). So, let’s get started. Overdosage There is no specific treatment in the event of Olaparib overdose, and symptoms of overdose are not established. In the event of an overdose, physicians should follow general supportive measures and should treat the patient symptomatically.
In this article, we will discuss Olaparib (Renal Impairment). So, let’s get started. Renal Impairment No adjustment to the starting dose is required in patients with mild renal impairment, but patients should be monitored closely for toxicity. A 24% increase in mean exposure (AUC) was observed in patients with mild renal impairment (CLcr = 51-80 […]